Buchumschlag

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Manya Prasad, Tushar Prabhakar, Shiv Kumar Sarin
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
von: Abdel‐Aziz Shaheen, et al.
Veröffentlicht: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
von: Samer Gawrieh, et al.
Veröffentlicht: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
von: Richie Manikat, et al.
Veröffentlicht: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Editorial: Quantity is important! Authors' reply
von: Marika Rudler, et al.
Veröffentlicht: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
von: Eunice X. X. Tan, et al.
Veröffentlicht: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
von: Mikkel Malham, et al.
Veröffentlicht: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
von: Richie Manikat, et al.
Veröffentlicht: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
von: Kyuwon Kim, et al.
Veröffentlicht: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
von: Stuart McPherson, et al.
Veröffentlicht: (2024)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
von: Stephanie A. Vuijk, et al.
Veröffentlicht: (2024)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
von: Benedikt Silvester Hofer, et al.
Veröffentlicht: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
von: Abhinav Vasudevan, et al.
Veröffentlicht: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
von: Nabil Noureddin, et al.
Veröffentlicht: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
von: Nina Løn, et al.
Veröffentlicht: (2024)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
von: Nipun Verma, et al.
Veröffentlicht: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
von: C. M. Fernández‐Rodríguez, et al.
Veröffentlicht: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
von: María Hernández‐Pérez, et al.
Veröffentlicht: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index (DASI) in predicting mortality and guiding prehabilitation. Authors' reply
von: Matthew J. Armstrong, et al.
Veröffentlicht: (2024)

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests? Authors' reply
von: Maria Gabriela Fernandes Dezan, et al.
Veröffentlicht: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
von: Dipesh H. Vasant, et al.
Veröffentlicht: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
von: Linda Henry, et al.
Veröffentlicht: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
von: Yewan Park, et al.
Veröffentlicht: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
von: Mohamad Jamalinia, et al.
Veröffentlicht: (2024)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
von: Lana Bridi, et al.
Veröffentlicht: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
von: R. M. Mathias, et al.
Veröffentlicht: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2024)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
von: Hsin‐Che Lin, et al.
Veröffentlicht: (2024)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply
von: Marta Paula Pereira Coelho, et al.
Veröffentlicht: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
von: Kyle Staller, et al.
Veröffentlicht: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
von: Tomohiro Fukuda, et al.
Veröffentlicht: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
von: María José García, et al.
Veröffentlicht: (2024)

Editorial: Eosinophilic oesophagitis coming of age—Increasing frequency and wider age range—Authors' reply
von: Akshatha Kiran, et al.
Veröffentlicht: (2024)

Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply
von: Tarek Hassanein, et al.
Veröffentlicht: (2024)

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population
von: Antonio De Vincentis, et al.
Veröffentlicht: (2024)

Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey
von: Rocio Enriquez, et al.
Veröffentlicht: (2024)